Lymphomas: Why I Would Refer a Lymphoma Patient to Memorial Sloan Kettering

By Anas Younes , MD  |  Thursday, August 7, 2014

I can think of many reasons to refer a patient with newly diagnosed or relapsed/refractory Hodgkin or non-Hodgkin lymphoma to Memorial Sloan Kettering.

But my top five are these:

Our Extensive Experience

The collective knowledge of our lymphoma experts is unparalleled around the globe. Many of our 12 full-time faculty members have more than 20 years of experience in diagnosing and managing patients with lymphoma. More importantly, the disease management team that involves these and other specialists — including medical oncologists, hematopathologists, and diagnostic radiologists — meets each week to discuss difficult cases. Our group also discusses all newly referred patients on a weekly basis to ensure a uniform management approach.

This consistency and breadth of shared knowledge helps to ensure that patients receive the best treatment options possible in the world today. Our team has extensive experience in managing even the rarest types of lymphomas, such as Burkitt lymphoma, Waldenstrom macroglobulinemia, and different types of T cell lymphoma.

Our Lymphoma Service is tight-knit, and we continue to add to it: We were pleased to welcome one of our star fellows, medical oncologist and hematologist Anita Kumar, as a full-time faculty member in August 2014.

Our Streamlined Efficiency

The average time from when patients first call us to when we see them in our clinic is five days. We achieve this through the use of a centralized referral process (call 800-525-2225 from Monday through Friday, 8:30 AM to 5:30 PM ET). Many of our referring physicians also continue to contact faculty members directly to discuss patients before deciding to make a referral or having a patient make an appointment.

Our Innovative Treatments

While we continue to provide state-of-the-art care to all of our patients, our numerous clinical trials also offer innovative treatment options, from the use of small molecule inhibitors to genetically engineered T cells for relapsed lymphoma and strategies aimed at stimulating the patient’s own immune cells to fight lymphoma. Our continuously updated clinical trials listings reveal the breadth and scope of our portfolio.

Our Cutting-Edge Facilities

Recently opened at our 64th Street Outpatient Center, our new “clinic of the future” provides an ideal environment to enhance the patient experience and promote education and interaction with our team while ensuring the utmost comfort for family members and caregivers.

Our Personalized Care

Many treatment options are available to people with lymphomas today. With recent advances in our understanding of the varying biology, proteomic biomarkers, and genetics of each person’s lymphoma, our approach to each patient is becoming increasingly individualized. Treatment options can now be tailored to provide patients with the most promising treatments based on their specific tumor type.